CONTENTS
December 2006
Nicholas White and François Nosten have shown that drugs in combination with artemisinin are 90% effective at fighting the scourge of the world. So why isn't everyone using it? MERRILL GOOZNER travels to Thailand and China to watch Nosten and White at work. |
RELATED: A military outbreak spurs research Slideshow: photos from Goozner's travels, including a stop at a clinic conducting artemisinin trials |
FIFTY YEARS WITH DOUBLE-STRANDED RNA MIT's ALEXANDER RICH, who discovered RNA hybridization in 1956, describes what it has meant to biology. It all started, he says, when he used to walk into the basement of the Cal Tech chemistry department.
|
RELATED: An interactive look at original documents with commentary: The discovery of the dsRNA helix, 1956 |
A LONG SHOT ON CYTOMEGALOVIRUS Gerd Maul, an unlikely vaccinologist, fights an unlikely foe. Join ALAN DOVE as he visits Maul's lab to find out why the scientist is trying to come up with a vaccine for a virus most people caught years ago and few will likely ever notice. 
Podcast: A vaccine for cytomegalovirus |
RELATED: Developing a hybrid CMV vaccine An economic boost for an unlikely target |
As the agency celebrates its 100th anniversary, what's next? TED AGRES finds out what Congress has in store. |
RELATED: Just another day at the office? |
Is Bush science's nemesis? Bird flu: Preventing paranoia EDITORIAL Just One Vote: The new US political landscape might be just different enough to boost stem cell research. White Paper How to Treat Premature Infants: A Nuffield Council Working Party takes on ethical issues in neonatal critical care. COLUMNS Want Fish? Ethics First, Please:
Why we should worry about the upcoming fish apocalypse. Intelligent Design: The Clincher. A butterfly explodes the theory. Notebook The frog robot condom; Filter my blood, please; When biodiversity makes you sick; Use the force, bacteria; From chemist to cook Foundations An automated PCR prototype, circa 1985 Profiles Physics Meets the Brain: How Terry Sejnowski went from a grad student in theoretical physics to computational neuroscience's White Knight. Scientist to Watch: Victoria Orphan BioBusiness Profile: Mersana CEO Julie Olsen. What happens when someone leaves cutting deals at pharma giant Pfizer for the life at a start up? The Literature Hot Paper: A double life for mTOR, the target of rapamycin, muddies its role in cancer. Leads on the obesity-diabetes link A candidate for transduction in hearing How trypanosomes move into the brain Lab Tools Who wants the X Prize for human genome sequencing? How to troubleshoot quantitative Q-PCR CAREERS What will your 2006 bonus look like?
|
|